Pacemaker Programmer Clinician Interface Patent Landscape
This field is heavily concentrated, with the top five filers accounting for 82% of the hundred largest filers’ combined patent records and Cardiac Pacemakers Inc holding the leading position. Annual filing volume peaked in 2019 and has since eased, placing the field in a decline stage—though adjacent branches in healthcare informatics and digital data processing remain sparsely covered.
A highly consolidated field led by established cardiac-device incumbents
Cardiac Pacemakers Inc leads the applicant ranking with 57 patent records, followed by Pacesetter Inc at 45 and Medtronic Inc at 23. The top tier is composed entirely of established cardiac-rhythm-management device manufacturers.
The top five filers—Cardiac Pacemakers Inc, Pacesetter Inc, Medtronic Inc, Biotronik SE & Co KG, and Impulse Dynamics NV—together account for 82% of the hundred largest filers’ combined patent records, signaling a tight oligopoly with a substantial gap to the second tier. Entrants ranked sixth and below hold five records or fewer each.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Cardiac Pacemakers Inc | 57 | |
| 2 | Pacesetter Inc | 45 | |
| 3 | Medtronic Inc | 23 | |
| 4 | BIOTRONIK SE & CO KG | 17 | |
| 5 | Impulse Dynamics NV | 7 | |
| 6 | Cirtec Medical Corp | 5 | |
| 7 | CvrX Inc | 5 | |
| 8 | MicroPort Sorin CRM (Shanghai) Co Ltd | 3 | |
| 9 | Medtronic Urinary Solutions | 2 | |
| 10 | Axonics Inc | 2 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Roseanne Satz | 2 | |
| 12 | Advanced Neuromodulation Systems Inc | 2 | |
| 13 | James David Webb | 2 | |
| 14 | E Bio Corp | 2 | |
| 15 | Olga Bockeria | 2 | |
| 16 | Philip Chidi Njemanze | 1 | |
| 17 | William R Mass | 1 | |
| 18 | Intermedics Inc | 1 | |
| 19 | Nuvectra Corp | 1 | |
| 20 | Tera Tech Corp | 1 |
The depth of the leaders’ positions in core electrotherapy (A61N) suggests that foundational programmer-interface IP is well defended, raising barriers for new entrants targeting the primary technology route. Differentiation through adjacent technical areas is likely necessary for late-arriving players.
The most recent 18–24 months of filing data are subject to publication lag and should be treated as undercounted; the apparent drop in 2024–2025 activity does not necessarily reflect a further reduction in actual filing rates.
A 2019 peak, irregular annual volumes, and a dominant electrotherapy core
The annual filing trend reveals a pronounced spike in 2019, followed by variable but generally lower annual volumes; the technology composition shows near-total dominance by the A61N electrotherapy class alongside sparse coverage in informatics and digital processing branches.
Annual filing trend
Filings rose sharply to a peak of 22 records in 2019, then retreated to a range of 5–17 records per year through 2023. Data for 2024 and 2025 are likely undercounted due to publication lag and should not be interpreted as a continuation of decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (electrotherapy and radiation therapy) dominates the technology mix overwhelmingly, with A61B (diagnosis and surgery) as a distant secondary class. Healthcare informatics (G16H), electric digital data processing (G06F), and transmission (H04B) each represent single-digit record counts, marking them as structurally sparse relative to the core.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Preserving patient specific data in implantable pu…
A method and a system for preserving patient specific data in implantable pulse generator systems. A communication link is established with a first implantable pulse generator. Electronic cardiac data contained within the first implantable pulse generator is retrieved through the communication link. The electronic cardiac data is then electronically… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Thin film electrodes for sensing cardiac depolariz… | 209 |
| 2 | System and method for atrial autocapture in single… | 191 |
| 3 | System and method for implantable device with one … | 126 |
| 4 | Leadless pacemaker with improved conducted communi… | 118 |
| 5 | Dual chamber leadless pacemaker programmer and met… | 115 |
| 6 | System and method for ventricular capture using fa… | 106 |
| 7 | Implantable cardiac monitor upgradeable to pacemak… | 97 |
| 8 | Dual chamber leadless pacemaker programmer and met… | 81 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D prioritization
The combination of high concentration, a post-peak filing trajectory, and a single dominant technology class shapes where entry barriers are highest and where room remains for differentiated investment.
Field is in decline from a 2019 peak
The lifecycle evidence places this field in a Decline stage: annual filings have eased back from the 2019 peak of 22 records and have not recovered to that level. This suggests the core programmer-interface IP landscape has passed its most active filing period, and foundational claims are largely staked. R&D investment should account for a maturing, defended core before committing to head-on competition.
Lifecycle: Decline82% share among top five filers signals a tight oligopoly
The top five filers hold 82% of the hundred largest filers’ combined patent records, with Cardiac Pacemakers Inc alone accounting for 57 records. The gap between the top tier and the remainder of the field is substantial—no applicant ranked sixth or below holds more than five records. Challenging the core through conventional prosecution is a high-cost, low-probability path for new entrants.
High concentrationNo co-applicant activity detected in this corpus
The collaboration evidence for this topic is empty: no co-applicant filings have been identified among the records in scope. The field appears to be driven exclusively by single-entity filings, consistent with large device manufacturers protecting proprietary programmer architectures independently. This also means no established consortium or open-innovation pathway is visible from the current data.
No co-filing detectedUS-centric filing with selective EPO and PCT extension
The United States is the dominant filing jurisdiction, followed by Europe (EPO) and WIPO (PCT). A smaller number of records extend to Austria, Australia, Israel, Canada, Germany, India, and Japan. The strong US lead reflects both the headquarters of the top applicants and the size of the US cardiac-device market. Applicants seeking global protection appear to prioritize EPO and PCT routes selectively rather than pursuing broad national-phase entry.
US-led, EPO/PCT secondaryGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
Co-filing pairs, ranked by the number of jointly-filed patent families.
Cardiac Pacemakers Inc and Pacesetter Inc anchor the field; newer momentum from Medtronic and Biotronik
The two largest filers have long-established positions concentrated in core electrotherapy IP, while Medtronic and Biotronik show new-entrant momentum signals in the most recent period—though these are flagged as new entrants and may reflect a small prior base.
Cardiac Pacemakers Inc
With 57 patent records—the largest position in the corpus—Cardiac Pacemakers Inc focuses primarily on A61N 1 (electrotherapy) with secondary coverage in A61B 5 (diagnosis and surgery). Momentum evidence indicates a new-entrant trend in the most recent period, which given the small recent count against their large historical base likely reflects publication lag rather than a genuine new entry phase. Their depth in core electrotherapy IP represents the highest barrier in the field.
57 patent recordsMedtronic Inc
Medtronic Inc holds 23 patent records and shows a new-entrant momentum trend in the recent window. Its technology focus spans A61N 1 (electrotherapy), A61B 5 (diagnosis and surgery), and G16H 40 (healthcare informatics)—the last of these being notable as one of the sparse adjacent branches. This broader IPC coverage differentiates Medtronic from the two leading filers and positions it as the player most actively exploring the informatics-adjacent space.
23 patent records| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Cardiac Pacemakers Inc | 1 | ▲ new entrant |
| Pacesetter Inc | 8 | ▼ -60% |
| Medtronic Inc | 8 | ▲ new entrant |
| Biotronik SE & Co KG | 9 | ▲ new entrant |
| Impulse Dynamics NV | 7 | ▲ new entrant |
Under-served branches in informatics and digital processing warrant monitoring
Three IPC branches adjacent to the dominant A61N core show sparse coverage relative to the overall corpus; each has plausible technical relevance to evolving clinician-interface requirements but lacks the filing depth that would signal active competition.
G16H · Healthcare informatics
This branch holds 10 patent records and represents 4% of the technology composition—the least-covered of the three adjacent classes. As pacemaker programmers increasingly integrate with electronic health record systems, remote monitoring platforms, and clinical decision-support tools, the informatics layer becomes a realistic technical frontier. Medtronic is the only top-five filer with visible G16H coverage (G16H 40), suggesting the branch is accessible to a focused entrant with a software-enabled programmer architecture. Entry path: data-integration middleware or remote-programming workflow software.
Search this in Eureka →G06F · Electric digital data processing
Nine patent records fall under G06F, representing 3% of the technology composition. Digital data processing is directly relevant to the user-interface software, algorithm display, and data visualization layers of a clinician programmer. Pacesetter Inc has G06F 17 coverage and Nuvectra Corp has G06F 19, but the branch remains structurally sparse. An entrant building advanced UI frameworks, parameter-optimization algorithms, or machine-learning-driven parameter suggestions could find this branch comparatively open relative to the heavily defended A61N core.
Search this in Eureka →Frequently asked questions
The evidence corpus covers 91 patent families. This figure represents the deduplicated family count and is the appropriate measure of unique inventions in scope.
Cardiac Pacemakers Inc leads with 57 patent records, well ahead of the second-ranked Pacesetter Inc at 45. Both are focused primarily on the A61N 1 (electrotherapy) IPC class.
The lifecycle evidence places the field in a Decline stage. Annual filings peaked in 2019 at 22 records and have not returned to that level. Data for 2024 and 2025 are subject to publication lag and should not be read as confirming further decline.
The United States is the primary filing jurisdiction, followed by Europe (EPO) and WIPO (PCT). A smaller number of records cover Austria, Australia, Israel, Canada, Germany, India, and Japan, indicating selective rather than broad international extension by most applicants.
Three adjacent IPC branches are structurally sparse: G16H (healthcare informatics) at 10 patent records, G06F (electric digital data processing) at 9 records, and H04B (transmission, general) at 3 records. These sit well below the dominant A61N class and may offer more room for differentiated filing strategies, though they should be assessed for commercial relevance before committing R&D resources.
Momentum evidence flags Medtronic Inc, Biotronik SE & Co KG, and Impulse Dynamics NV as new entrants in the most recent period, while Pacesetter Inc shows a downward trend of -60% versus the prior three-year window. Cardiac Pacemakers Inc also carries a new-entrant flag in the recent period, which likely reflects publication lag given their large historical position.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.